Nothing Special   »   [go: up one dir, main page]

IL114477A - A process for the enantioselective synthesis of converted sulfoxides, individual enantiomers obtained as a result of the process and their use in the preparation of drugs - Google Patents

A process for the enantioselective synthesis of converted sulfoxides, individual enantiomers obtained as a result of the process and their use in the preparation of drugs

Info

Publication number
IL114477A
IL114477A IL11447795A IL11447795A IL114477A IL 114477 A IL114477 A IL 114477A IL 11447795 A IL11447795 A IL 11447795A IL 11447795 A IL11447795 A IL 11447795A IL 114477 A IL114477 A IL 114477A
Authority
IL
Israel
Prior art keywords
alkyl
hydrogen
chiral
alkoxy
benzimidazole
Prior art date
Application number
IL11447795A
Other languages
English (en)
Hebrew (he)
Other versions
IL114477A0 (en
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20394753&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL114477(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astra Ab filed Critical Astra Ab
Publication of IL114477A0 publication Critical patent/IL114477A0/xx
Publication of IL114477A publication Critical patent/IL114477A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/28—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Catalysts (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IL11447795A 1994-07-15 1995-07-06 A process for the enantioselective synthesis of converted sulfoxides, individual enantiomers obtained as a result of the process and their use in the preparation of drugs IL114477A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9402510A SE504459C2 (sv) 1994-07-15 1994-07-15 Förfarande för framställning av substituerade sulfoxider

Publications (2)

Publication Number Publication Date
IL114477A0 IL114477A0 (en) 1995-11-27
IL114477A true IL114477A (en) 2001-07-24

Family

ID=20394753

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11447795A IL114477A (en) 1994-07-15 1995-07-06 A process for the enantioselective synthesis of converted sulfoxides, individual enantiomers obtained as a result of the process and their use in the preparation of drugs

Country Status (42)

Country Link
US (1) US5948789A (de)
EP (1) EP0773940B2 (de)
JP (1) JP3795917B2 (de)
KR (1) KR100356252B1 (de)
CN (1) CN1070489C (de)
AR (1) AR003443A1 (de)
AT (1) ATE242233T1 (de)
AU (1) AU688074B2 (de)
BR (1) BR9508292A (de)
CA (1) CA2193994C (de)
CZ (1) CZ297987B6 (de)
DE (1) DE69530987T3 (de)
DK (1) DK0773940T4 (de)
DZ (1) DZ1911A1 (de)
EE (1) EE03354B1 (de)
EG (1) EG24534A (de)
ES (1) ES2199998T5 (de)
FI (2) FI117830B (de)
HK (1) HK1008331A1 (de)
HR (1) HRP950401B1 (de)
HU (1) HU226361B1 (de)
IL (1) IL114477A (de)
IS (1) IS1772B (de)
MA (1) MA23611A1 (de)
MX (1) MX9700358A (de)
MY (1) MY113180A (de)
NO (1) NO312101B1 (de)
NZ (1) NZ289959A (de)
PL (1) PL186342B1 (de)
PT (1) PT773940E (de)
RU (1) RU2157806C2 (de)
SA (1) SA95160294B1 (de)
SE (1) SE504459C2 (de)
SI (1) SI0773940T2 (de)
SK (1) SK284059B6 (de)
TN (1) TNSN95081A1 (de)
TR (1) TR199500861A2 (de)
TW (1) TW372971B (de)
UA (1) UA47409C2 (de)
WO (1) WO1996002535A1 (de)
YU (1) YU49475B (de)
ZA (1) ZA955724B (de)

Families Citing this family (153)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6875872B1 (en) 1993-05-28 2005-04-05 Astrazeneca Compounds
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
SE504459C2 (sv) * 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6747155B2 (en) 1997-05-30 2004-06-08 Astrazeneca Ab Process
SE510650C2 (sv) 1997-05-30 1999-06-14 Astra Ab Ny förening
SE510643C2 (sv) * 1997-06-27 1999-06-14 Astra Ab Termodynamiskt stabil omeprazol natrium form B
PL337888A1 (en) 1997-07-03 2000-09-11 Du Pont Pharm Co Imidazoprimidines and imidazopyridines for use in treating neurological disorders
US6096340A (en) 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
SE9704183D0 (sv) * 1997-11-14 1997-11-14 Astra Ab New process
AU742620B2 (en) * 1998-01-30 2002-01-10 Sepracor, Inc. R-lansoprazole compositions and methods
WO1999055158A1 (en) * 1998-04-30 1999-11-04 Sepracor Inc. S-rabeprazole compositions and methods
JP2002512262A (ja) * 1998-04-30 2002-04-23 セプラコール， インク． Ｒ−レイブプラゾール組成物及び方法
US6365589B1 (en) 1998-07-02 2002-04-02 Bristol-Myers Squibb Pharma Company Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists
US6733778B1 (en) 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
CN1087739C (zh) * 1998-12-28 2002-07-17 中国科学院成都有机化学研究所 光学纯的苯并咪唑类抗消化性溃疡药物的包结拆分制备法
SE9900274D0 (sv) * 1999-01-28 1999-01-28 Astra Ab New compound
TWI275587B (en) 1999-06-17 2007-03-11 Takeda Chemical Industries Ltd A crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
AU5705700A (en) 1999-06-30 2001-01-22 Takeda Chemical Industries Ltd. Crystals of benzimidazole compounds
AU6727700A (en) * 1999-08-25 2001-03-19 Takeda Chemical Industries Ltd. Process for the preparation of optically active sulfoxide derivatives
US6262086B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Pharmaceutical unit dosage form
US6780880B1 (en) 1999-08-26 2004-08-24 Robert R. Whittle FT-Raman spectroscopic measurement
US6262085B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6312723B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Pharmaceutical unit dosage form
US6316020B1 (en) * 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6268385B1 (en) 1999-08-26 2001-07-31 Robert R. Whittle Dry blend pharmaceutical formulations
US6312712B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Method of improving bioavailability
US6326384B1 (en) 1999-08-26 2001-12-04 Robert R. Whittle Dry blend pharmaceutical unit dosage form
US6982275B2 (en) 2000-04-28 2006-01-03 Takeda Pharmaceutical Company Limited Process for producing optically active sulfoxide derivative
EP2281821B1 (de) 2000-05-15 2014-10-22 Takeda Pharmaceutical Company Limited Verfahren zur Herstellung eines Kristalls von (R)-2-[[[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]benzimidazol
KR100869677B1 (ko) 2000-05-15 2008-11-21 다케다 야쿠힌 고교 가부시키가이샤 결정의 제조방법
WO2002012225A1 (fr) * 2000-08-04 2002-02-14 Takeda Chemical Industries, Ltd. Sels de composé à base de benzimidazole et leurs applications
DK1337525T3 (da) 2000-12-01 2011-09-19 Takeda Pharmaceutical Fremgangsmåde til krystallisering af (R)- eller (S)-lansoprazol
US7064214B2 (en) * 2001-04-13 2006-06-20 Apsinterm Llc Methods of preparing sulfinamides and sulfoxides
GB2376231A (en) * 2001-06-06 2002-12-11 Cipla Ltd Benzimidazole-cyclodextrin inclusion complex
CA2472103A1 (en) * 2002-01-25 2003-08-07 Santarus, Inc. Transmucosal delivery of proton pump inhibitors
ES2286408T3 (es) 2002-03-05 2007-12-01 Astrazeneca Ab Sales de alquilamonio de omeprazol e esomeprazol.
AU2003262375A1 (en) * 2002-04-22 2003-11-03 Sun Pharmaceutical Industries Limited Optically active substituted pyridinylmethyl-sulphinyl-benzimidazole and salts
WO2004002982A2 (en) * 2002-06-27 2004-01-08 Dr. Reddy's Laboratories Limited A process for preparation of optically pure or optically enriched sulfoxide compounds, including amorphous esomeprazole and salts thereof
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
EP2596791B1 (de) * 2002-10-16 2015-04-01 Takeda Pharmaceutical Company Limited Stabile, feste Präparate
US20040235903A1 (en) 2002-10-22 2004-11-25 Khanna Mahavir Singh Amorphous form of esomeprazole salts
DE10254167A1 (de) 2002-11-20 2004-06-09 Icon Genetics Ag Verfahren zur Kontrolle von zellulären Prozessen in Pflanzen
ATE553103T1 (de) 2002-12-06 2012-04-15 Nycomed Gmbh Verfahren zur herstellung von (s)-pantoprazol
AU2003289948B2 (en) 2002-12-06 2009-12-24 Takeda Gmbh Process for preparing optically pure active compounds
FR2848555B1 (fr) 2002-12-16 2006-07-28 Negma Gild Enantiomere(-)du tenatoprazole et son application en therapeutique
AU2003288576A1 (en) * 2002-12-16 2004-07-09 Ranbaxy Laboratories Limited Rabeprazole calcium
CA2510849A1 (en) 2002-12-19 2004-07-08 Teva Pharmaceutical Industries Ltd Solid states of pantoprazole sodium, processes for preparing them and processes for preparing known pantoprazole sodium hydrates
CN1723208A (zh) * 2003-01-07 2006-01-18 兰贝克赛实验室有限公司 咪唑衍生物的镁盐
US20040248942A1 (en) * 2003-02-20 2004-12-09 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
CN1777598A (zh) * 2003-02-28 2006-05-24 兰贝克赛实验室有限公司 S－奥美拉唑的多晶型物
ES2245277T1 (es) * 2003-03-12 2006-01-01 Teva Pharmaceutical Industries Limited Solidos cristalinos y amorfos de pantoprazol y procedimientos para su preparacion.
EP1611901B1 (de) * 2003-03-13 2013-07-10 Eisai R&D Management Co., Ltd. Mittel zur Prävention oder Heilung von Zähneknirschen
EP1608649A2 (de) * 2003-03-28 2005-12-28 Sidem Pharma SA Verfahren zur herstellung von enantioselektiven sulfoxid-derivaten
FR2852956B1 (fr) * 2003-03-28 2006-08-04 Negma Gild Procede de preparation enantioselective de derives de sulfoxydes
US20070060556A1 (en) * 2003-05-05 2007-03-15 Yatendra Kumar Barium salt of benzimidazole derivative
CA2528993A1 (en) 2003-06-10 2004-12-23 Teva Pharmaceutical Industries Ltd. Process for preparing 2-[(pyridinyl)methyl]sulfinyl-substituted benzimidazoles and novel chlorinated derivatives of pantoprazole
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
SE0302382D0 (sv) 2003-09-04 2003-09-04 Astrazeneca Ab New salts II
SE0302381D0 (sv) 2003-09-04 2003-09-04 Astrazeneca Ab New salts I
AU2003288703A1 (en) * 2003-12-05 2005-06-24 Hetero Drugs Limited A process for the preparation of substitited pyridinylmethylsulfinyl- benzimidazole enantiomers
SE0400410D0 (sv) * 2004-02-20 2004-02-20 Astrazeneca Ab New compounds
PT1740571E (pt) 2004-04-28 2009-09-02 Hetero Drugs Ltd Processo para preparar compostos de piridinilmetil-1hbenzimidazol na forma enantiomericamente enriquecida ou como enantiómeros únicos
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
ATE456566T1 (de) * 2004-05-28 2010-02-15 Hetero Drugs Ltd Neue stereoselektive synthese von benzimidazolsulfoxiden
CN1960987A (zh) * 2004-06-02 2007-05-09 奥坦纳医药公司 制备吡啶－2－基甲基亚磺酰基－1h－苯并咪唑类化合物的方法
US8461187B2 (en) 2004-06-16 2013-06-11 Takeda Pharmaceuticals U.S.A., Inc. Multiple PPI dosage form
US20080249134A1 (en) * 2004-06-24 2008-10-09 Ursula Hohlneicher New Esomeprazole Sodium Salt Crystal Modification
MXPA06015031A (es) 2004-06-24 2007-02-08 Astrazeneca Ab Nuevo proceso para la preparacion de modificaciones cristalinas para usarse en la preparacion de sal de sodio de esomeprazol.
FR2876101B1 (fr) * 2004-10-05 2007-03-02 Sidem Pharma Sa Sa Procede de preparation enantioselective de derives de sulfoxydes
WO2006040635A1 (en) * 2004-10-11 2006-04-20 Ranbaxy Laboratories Limited Processes for the preparation of substituted sulfoxides
US7592111B2 (en) * 2004-11-05 2009-09-22 Xerox Corporation Imaging member
CN101098867B (zh) * 2005-03-25 2010-08-11 丽珠医药集团股份有限公司 取代的亚砜类化合物和其制备方法及用途
US20060217423A1 (en) 2005-03-25 2006-09-28 Jingen Deng Substituted sulfoxide compounds, methods for preparing the same and use thereof
KR20080007508A (ko) * 2005-05-06 2008-01-21 그렌마크 파머수티칼스 엘티디. 에소메프라졸 스트론튬염, 그것의 제조방법 및 그것을함유하는 약제학적 조성물
JP2008545768A (ja) * 2005-06-08 2008-12-18 レツク・フアーマシユーテイカルズ・デー・デー オメプラゾールナトリウムの結晶性溶媒和物
US20070043085A1 (en) * 2005-08-19 2007-02-22 Glenmark Pharmaceuticals Limited Process for the preparation of amorphous form of neutral esomeprazole
JP2009518394A (ja) 2005-12-05 2009-05-07 アストラゼネカ・アクチエボラーグ エソメプラゾールの非塩形態の新規の製造方法
DE102005061720B3 (de) * 2005-12-22 2006-10-19 Ratiopharm Gmbh Enantioselektive Herstellung von Benzimidazolderivaten und ihren Salzen
EP1801110A1 (de) 2005-12-22 2007-06-27 KRKA, tovarna zdravil, d.d., Novo mesto Argininsalz des Esomeprazols
US7553857B2 (en) 2005-12-23 2009-06-30 Lek Pharmaceuticals D.D. S-omeprazole magnesium
DE602006006352D1 (de) 2005-12-28 2009-05-28 Union Quimico Farma Verfahren zur herstellung des (s)-enantiomers von omeprazol
CN1810803B (zh) * 2006-02-17 2010-11-17 中国科学院上海有机化学研究所 高对映体选择性制备(s)-奥美拉唑的方法
US7579476B2 (en) * 2006-02-24 2009-08-25 Praktikatalyst Pharma, Llc Transition metal mediated oxidation of hetero atoms in organic molecules coordinated to transition metals
US8063074B2 (en) * 2006-05-04 2011-11-22 Dr. Reddy's Laboratories Limited Polymorphic forms of esomeprazole sodium
US7786309B2 (en) * 2006-06-09 2010-08-31 Apotex Pharmachem Inc. Process for the preparation of esomeprazole and salts thereof
EP2038271A1 (de) 2006-07-05 2009-03-25 Lupin Limited Verfahren zur herstellung von optisch reinen oder optisch angereicherten enantiomeren von sulfoxidverbindungen
CA2660112A1 (en) * 2006-08-08 2008-02-14 Jubilant Organosys Limited Process for producing sulphoxide compounds
JP2009196894A (ja) * 2006-10-13 2009-09-03 Eisai R & D Management Co Ltd スルフィニルベンズイミダゾール化合物またはその塩の製造方法
JP5492417B2 (ja) 2006-10-13 2014-05-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 胃酸分泌抑制作用を有するベンズイミダゾール化合物
EP1947099A1 (de) 2007-01-18 2008-07-23 LEK Pharmaceuticals D.D. Verfahren zur Entfernung von Lösungsmitteln in Omeprazol-Salzen
JP2010519284A (ja) 2007-02-21 2010-06-03 シプラ・リミテッド エソメプラゾールマグネシウム二水和物の調製方法
ATE534643T1 (de) * 2007-06-07 2011-12-15 Aurobindo Pharma Ltd Verbessertes verfahren zur herstellung eines optisch aktiven protonenpumpenhemmers
CN101323609B (zh) * 2007-06-15 2013-05-01 成都福瑞生物工程有限公司 不对称氧化硫醚成亚砜合成对映体含量高的苯并咪唑衍生物的方法
US20100210848A1 (en) * 2007-10-03 2010-08-19 Ipca Laboratories Ltd. Process for optically active sulfoxide compounds
WO2009047775A2 (en) 2007-10-08 2009-04-16 Hetero Drugs Limited Polymorphs of esomeprazole salts
RU2013106514A (ru) 2007-10-12 2015-03-10 Такеда Фармасьютикалз Норт Америка, Инк. Способы лечения нарушений желудочно-кишечного тракта независимо от потребления пищи
FR2925899B1 (fr) * 2007-12-27 2012-12-21 Sidem Pharma Sa Procede de preparation enantioselective de sulfoxydes.
CN101492459B (zh) * 2008-01-25 2011-04-27 山东轩竹医药科技有限公司 含烷氧乙酰基二氢异噁唑并吡啶化合物
CN101497603B (zh) * 2008-01-30 2012-11-07 山东轩竹医药科技有限公司 含有被烷氧烷胺氧基取代的吡啶的苯并咪唑衍生物
EP2262790B1 (de) 2008-03-10 2017-06-07 Takeda Pharmaceutical Company Limited Kristall einer benzimidazolverbindung
US20110028518A1 (en) * 2008-03-18 2011-02-03 Dr. Reddy's Laboratories Ltd. Dexlansoprazole process and polymorphs
CN101538264A (zh) * 2008-03-19 2009-09-23 中国科学院成都有机化学有限公司 手性亚砜类化合物的制备新方法
WO2009145368A1 (en) * 2008-05-27 2009-12-03 Sk Chemicals Co., Ltd. Improved preparing method of (s)-omeprazole from omeprazole racemate using optical resolution agent
EP2143722A1 (de) 2008-07-09 2010-01-13 Lek Pharmaceuticals D.D. Verfahren zur Herstellung von Esomeprazol-Natrium von hoher chemischer Reinheit und neue Formen von Esomeprazol-Natrium
WO2010039885A2 (en) * 2008-09-30 2010-04-08 Teva Pharmaceutical Industries Ltd. Crystalline forms of dexlansoprazole
EP2264024A1 (de) 2008-10-14 2010-12-22 LEK Pharmaceuticals d.d. Verfahren zur Herstellung einer enantiomerisch-angereicherte Protonpumpenhemmer
IT1391776B1 (it) 2008-11-18 2012-01-27 Dipharma Francis Srl Procedimento per la preparazione di dexlansoprazolo
CZ200990A3 (cs) * 2009-02-16 2010-08-25 Zentiva, K.S. Zpusob výroby (S)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazolu
WO2010097583A1 (en) 2009-02-24 2010-09-02 Cipla Limited Esomeprazole potassium polymorph and its preparation
CZ2009172A3 (cs) * 2009-03-17 2010-09-29 Zentiva, K.S. Zpusob výroby (S)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazolu
EP2438057A4 (de) * 2009-06-02 2013-12-25 Sun Pharmaceutical Ind Ltd Verfahren zur herstellung von sulfoxidverbindungen
IT1395118B1 (it) 2009-07-29 2012-09-05 Dipharma Francis Srl Procedimento per la preparazione di dexlansoprazolo cristallino
WO2011058569A1 (en) 2009-11-12 2011-05-19 Hetero Research Foundation Process for the resolution of omeprazole
CA2788147A1 (en) 2010-01-29 2011-08-04 Ranbaxy Laboratories Limited Process for the preparation of crystalline forms of dexlansoprazole
CA2803673A1 (en) 2010-06-24 2011-12-29 Cipla Limited Salts and polymorphs of dexrabeprazole
CN101914090B (zh) * 2010-08-13 2013-03-20 埃斯特维华义制药有限公司 左旋奥美拉唑的制备方法
CN102558150B (zh) * 2010-12-31 2014-03-12 正大天晴药业集团股份有限公司 取代亚砜化合物的合成方法
CN102321071B (zh) * 2011-07-20 2013-01-23 江苏奥赛康药业股份有限公司 一种高纯度埃索美拉唑钠的工业化生产方法
CN102977076A (zh) * 2011-09-02 2013-03-20 扬子江药业集团上海海尼药业有限公司 一种右兰索拉唑的制备方法
CN102329302A (zh) * 2011-10-22 2012-01-25 刘强 一种埃索美拉唑及其盐的制备方法
CN102408412A (zh) * 2011-10-25 2012-04-11 广东华南药业集团有限公司 高对映体选择性制备（s）- 奥美拉唑的方法
CN102432412A (zh) * 2011-10-28 2012-05-02 成都欣捷高新技术开发有限公司 一种手性亚砜类质子泵抑制剂或其可药用盐的制备方法
KR101300950B1 (ko) * 2011-10-31 2013-08-27 르노삼성자동차 주식회사 전기자동차의 공기 흡입 장치
WO2013140120A1 (en) 2012-03-22 2013-09-26 Cipla Limited Glycerol solvate forms of (r) - 2 - [ [ [3 -methyl -4 (2,2, 2 - trifluoroethoxy) pyridin- 2 - yl] methyl] sulphinyl] - 1h - ben zimidazole
CN102633776B (zh) * 2012-03-28 2014-06-18 中山市仁合药业有限公司 一种埃索美拉唑及其钠盐的制备方法
CN102659763B (zh) * 2012-04-27 2014-01-22 南京优科生物医药研究有限公司 一种右旋兰索拉唑合成与纯化的方法
CN103044402B (zh) * 2012-12-31 2015-01-14 康普药业股份有限公司 埃索美拉唑钠合成生产方法
CN103113351B (zh) * 2013-03-08 2015-01-21 苏州特瑞药业有限公司 一种光学纯手性亚砜类化合物的制备方法
CN104177336A (zh) * 2013-05-28 2014-12-03 上海汇伦生命科技有限公司 一种对映选择性合成右兰索拉唑的方法
EP2933002A1 (de) 2014-04-11 2015-10-21 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmazeutische kombinationen von dabigatran und protonenpumpeninhibitoren
WO2015155307A1 (en) 2014-04-11 2015-10-15 Sanovel Ilac Sanayi Ve Ticaret A.S. Pharmaceutical combinations of rivaroxaban and proton pump inhibitors
EP2980086B1 (de) 2014-07-29 2016-06-15 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Effizientes Verfahren zur Herstellung von Esomeprazol (S)-Binol Komplex
KR20170098843A (ko) 2014-12-26 2017-08-30 고쿠리츠다이가쿠호우진 도쿄다이가쿠 광학 활성의 프로톤 펌프 저해 화합물의 제조 방법
CN104610226A (zh) * 2014-12-31 2015-05-13 广东东阳光药业有限公司 一种右兰索拉唑的不对称氧化方法
ES2615637T3 (es) * 2015-03-06 2017-06-07 F.I.S.- Fabbrica Italiana Sintetici S.P.A. Procedimiento mejorado para la purificación óptica del esomeprazol
CN105218392B (zh) * 2015-07-09 2017-11-21 天津青松华药医药有限公司 D‑酒石酸单酯单酰胺类化合物
CN105218391B (zh) * 2015-07-09 2017-11-21 天津青松华药医药有限公司 L‑酒石酸单酯单酰胺类化合物
CN105968097B (zh) * 2016-05-17 2019-05-03 杭州华东医药集团新药研究院有限公司 左旋泮托拉唑的工业化生产方法
CN106083818A (zh) * 2016-06-08 2016-11-09 扬子江药业集团有限公司 一种高纯度埃索美拉唑钠的制备方法
CN106366070B (zh) * 2016-08-10 2019-06-11 上海万巷制药有限公司 一种高纯度埃索美拉唑钠的制备方法
CN106632248A (zh) * 2016-09-30 2017-05-10 青岛云天生物技术有限公司 一种左旋泮托拉唑钠的制备工艺
CN106632249A (zh) * 2016-09-30 2017-05-10 青岛云天生物技术有限公司 一种制备(s)‑泮托拉唑钠的方法
CN106866630B (zh) * 2017-04-01 2018-08-07 上海华源医药科技发展有限公司 一种右兰索拉唑的制备方法
CN110746428A (zh) * 2019-10-29 2020-02-04 株洲千金药业股份有限公司 一种r型手性亚砜类化合物的制备方法
CN110698482A (zh) * 2019-10-29 2020-01-17 株洲千金药业股份有限公司 一种s型手性亚砜类化合物的制备方法
CN113845510A (zh) * 2020-06-27 2021-12-28 鲁南制药集团股份有限公司 一种埃索美拉唑的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
DE4035455A1 (de) * 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab Enantiomerentrennung
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
SE504459C2 (sv) * 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
GB9423970D0 (en) * 1994-11-28 1995-01-11 Astra Ab Oxidation
GB9423968D0 (en) * 1994-11-28 1995-01-11 Astra Ab Resolution

Also Published As

Publication number Publication date
DE69530987D1 (de) 2003-07-10
DE69530987T2 (de) 2004-05-19
HRP950401B1 (en) 2004-04-30
PT773940E (pt) 2003-10-31
IS1772B (is) 2001-06-01
CN1070489C (zh) 2001-09-05
TW372971B (en) 1999-11-01
FI117672B (fi) 2007-01-15
EE03354B1 (et) 2001-02-15
NO970153L (no) 1997-01-14
HRP950401A2 (en) 1997-10-31
FI970102A (fi) 1997-01-10
HK1008331A1 (en) 1999-05-07
PL186342B1 (pl) 2003-12-31
SE504459C2 (sv) 1997-02-17
AU2994895A (en) 1996-02-16
WO1996002535A1 (en) 1996-02-01
AU688074B2 (en) 1998-03-05
PL318165A1 (en) 1997-05-26
SE9402510L (sv) 1996-01-16
SE9402510D0 (sv) 1994-07-15
FI970102A0 (fi) 1997-01-10
EP0773940B1 (de) 2003-06-04
YU49475B (sh) 2006-05-25
KR100356252B1 (ko) 2002-11-18
ES2199998T3 (es) 2004-03-01
EP0773940B2 (de) 2010-11-17
EG24534A (en) 2009-08-30
CA2193994C (en) 2005-05-03
CA2193994A1 (en) 1996-02-01
UA47409C2 (uk) 2002-07-15
KR970704731A (ko) 1997-09-06
MA23611A1 (fr) 1996-04-01
IL114477A0 (en) 1995-11-27
CN1157614A (zh) 1997-08-20
FI117830B (fi) 2007-03-15
AR003443A1 (es) 1998-08-05
DK0773940T3 (da) 2003-09-15
RU2157806C2 (ru) 2000-10-20
SK4897A3 (en) 1997-08-06
SA95160294B1 (ar) 2006-07-31
DE69530987T3 (de) 2011-07-07
HUT76642A (en) 1997-10-28
BR9508292A (pt) 1997-12-23
SI0773940T1 (en) 2004-02-29
ZA955724B (en) 1996-01-15
IS4406A (is) 1996-12-27
TR199500861A2 (tr) 1996-06-21
CZ6497A3 (en) 1997-06-11
ES2199998T5 (es) 2011-03-16
EP0773940A1 (de) 1997-05-21
SK284059B6 (sk) 2004-09-08
MY113180A (en) 2001-12-31
NO312101B1 (no) 2002-03-18
HU226361B1 (en) 2008-09-29
JPH10504290A (ja) 1998-04-28
YU47695A (sh) 1998-07-10
NZ289959A (en) 1998-01-26
JP3795917B2 (ja) 2006-07-12
WO1996002535A8 (en) 1999-12-23
ATE242233T1 (de) 2003-06-15
NO970153D0 (no) 1997-01-14
SI0773940T2 (sl) 2011-02-28
CZ297987B6 (cs) 2007-05-16
MX9700358A (es) 1997-04-30
US5948789A (en) 1999-09-07
DK0773940T4 (da) 2011-02-07
DZ1911A1 (fr) 2002-02-17
TNSN95081A1 (fr) 1996-02-06

Similar Documents

Publication Publication Date Title
EP0773940B1 (de) Verfahren zur herstellung von substituierten sulfoxiden
JP4195507B2 (ja) エナンチオマーが富化されたベンゾイミダゾール誘導体を光学的に精製する方法
US7452998B2 (en) Process for preparing optically pure active compounds
US8697880B2 (en) Compounds useful for the synthesis of S- and R-omeprazole and a process for their preparation
MXPA98000160A (en) A process for the optic purification of derivatives of benzimidazol enriquecidos enantiomericame

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired